These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12084176)

  • 1. Sickle cell patients deserve controlled recommendations.
    Strauss RG
    Transfusion; 2002 May; 42(5):658-9; author reply 659-60. PubMed ID: 12084176
    [No Abstract]   [Full Text] [Related]  

  • 2. The future of red blood cell alloimmunization risk reduction.
    Karafin MS; Denomme GA; Bryant BJ
    Transfusion; 2015 Jan; 55(1):220-1. PubMed ID: 25582238
    [No Abstract]   [Full Text] [Related]  

  • 3. Prospective antigen matching strategies fail to fit the model.
    Webb J; Chou ST
    Transfusion; 2015 Jan; 55(1):221-2. PubMed ID: 25582239
    [No Abstract]   [Full Text] [Related]  

  • 4. The future of red blood cell alloimmunization risk reduction.
    Kacker S; Ness PM; Shirey RS; Savage WJ; King KE; Tobian AA
    Transfusion; 2015 Jan; 55(1):222-4. PubMed ID: 25582240
    [No Abstract]   [Full Text] [Related]  

  • 5. Red blood cell alloimmunization in sickle cell disease-prevalence and trends: a single-center cross-sectional study from United Kingdom.
    Mijovic A; Perera IG; Thein SL
    Transfusion; 2013 Dec; 53(12):3279-80. PubMed ID: 24320815
    [No Abstract]   [Full Text] [Related]  

  • 6. Red cell exchange does not appear to increase the rate of allo- and auto-immunization in chronically transfused children with sickle cell disease.
    Venkateswaran L; Teruya J; Bustillos C; Mahoney D; Mueller BU
    Pediatr Blood Cancer; 2011 Aug; 57(2):294-6. PubMed ID: 21298771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Red Blood Cell Antigen Matching on Alloimmunization and Transfusion Complications in Patients with Sickle Cell Disease: A Systematic Review.
    Fasano RM; Meyer EK; Branscomb J; White MS; Gibson RW; Eckman JR
    Transfus Med Rev; 2019 Jan; 33(1):12-23. PubMed ID: 30122266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease.
    Harm SK; Yazer MH; Monis GF; Triulzi DJ; Aubuchon JP; Delaney M
    Am J Clin Pathol; 2014 Feb; 141(2):256-61. PubMed ID: 24436274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells.
    Vichinsky EP
    Immunohematology; 2012; 28(1):20-3. PubMed ID: 22646146
    [No Abstract]   [Full Text] [Related]  

  • 10. Red cell transfusions for patients with sickle cell disease: do we have more to learn?
    Nuss R
    Pediatr Blood Cancer; 2010 Apr; 54(4):499-500. PubMed ID: 19998466
    [No Abstract]   [Full Text] [Related]  

  • 11. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
    Talano JA; Hillery CA; Gottschall JL; Baylerian DM; Scott JP
    Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosensitization in patients receiving multiple blood transfusions.
    Sakhalkar VS; Roberts K; Hawthorne LM; McCaskill DM; Veillon DM; Caldito GC; Cotelingam JD
    Ann N Y Acad Sci; 2005; 1054():495-9. PubMed ID: 16339705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. For the patient. Alloimmunization: one risk of treating sickle cell disease.
    Ethn Dis; 2010; 20(2):195. PubMed ID: 20506598
    [No Abstract]   [Full Text] [Related]  

  • 14. [Transfusion and sickle cell disease].
    Boulat C
    Transfus Clin Biol; 2013 May; 20(2):68-71. PubMed ID: 23597585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red blood cell alloimmunization: lessons from sickle cell disease.
    Treml A; King KE
    Transfusion; 2013 Apr; 53(4):692-5. PubMed ID: 23565994
    [No Abstract]   [Full Text] [Related]  

  • 16. Transfusion service management of sickle-cell disease patients.
    Yazer MH; Lozano M; Crighton G; Greenway A; Comande M; Savoia H; Wood E; Gilli S; Castilho L; Saad ST; Galactéros F; Noizat-Pirenne F; Pazgal I; Stark P; Orlin Y; Perseghin P; Masera N; Cela E; Anguita J; Wikman A; Delaney M
    Vox Sang; 2016 Apr; 110(3):288-94. PubMed ID: 26177989
    [No Abstract]   [Full Text] [Related]  

  • 17. Case reports: delayed hemolytic transfusion reaction in sickle cell disease.
    Syed SK; Sears DA; Werch JB; Udden MM; Milam JD
    Am J Med Sci; 1996 Oct; 312(4):175-81. PubMed ID: 8853066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfusion therapy for sickle cell disease: a balancing act.
    Chou ST
    Hematology Am Soc Hematol Educ Program; 2013; 2013():439-46. PubMed ID: 24319217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sickle cell anemia and transfusion safety in Bamako, Mali. Seroprevalence of HIV, HBV and HCV infections and alloimmunization belonged to Rh and Kell systems in sickle cell anemia patients].
    Diarra AB; Guindo A; Kouriba B; Dorie A; Diabaté DT; Diawara SI; Fané B; Touré BA; Traoré A; Gulbis B; Diallo DA
    Transfus Clin Biol; 2013 Dec; 20(5-6):476-81. PubMed ID: 23916574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
    Aygun B; Padmanabhan S; Paley C; Chandrasekaran V
    Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.